Chinese clinical oncology
-
Chinese clinical oncology · Dec 2016
Randomized Controlled Trial Multicenter StudyTransdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study.
The granisetron transdermal delivery system (GTDS) has been demonstrated effectiveness in the control of chemotherapy-induced nausea and vomiting (CINV) in previous studies. This is the first phase III study to evaluate the efficacy and tolerability of GTDS in patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC) in China. ⋯ GTDS provided effective and well-tolerated control of CINV in Chinese patients, especially to non-cisplatin-contained regimen.
-
Although the science is able to proof that a drug works for the BRCA mutation in breast cancer, prostate cancer and pancreatic cancer (and maybe in other BRCA-mutated cancers) we stick to the registration path of doing phase 1, 2 and 3 trials based on organs. With the knowledge of today and the practice of personalized medicine we are able to give the drug olaparib much faster and save lives or at least extend lives with a good quality of life. This can be done differently if patients are involved in the process of determining the research, designing the trials and organizing the trials. If done properly we help patients in the first place and all the stakeholders will benefit as well.